These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6761867)

  • 1. Preclinical toxicology of ifosfamide.
    Barnett D
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):8-13. PubMed ID: 6761867
    [No Abstract]   [Full Text] [Related]  

  • 2. Isophosphamide.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1981 May; 26():237-47. PubMed ID: 6944261
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates.
    Kuśnierczyk H; Radzikowski C; Paprocka M; Budzyński W; Rak J; Kinas R; Misiura K; Stec W
    J Immunopharmacol; 1986; 8(4):455-80. PubMed ID: 3805744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide in experimental tumor systems.
    Goldin A
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):14-23. PubMed ID: 6761864
    [No Abstract]   [Full Text] [Related]  

  • 5. Ifosfamide--pharmacology, safety and therapeutic potential.
    Brade WP; Herdrich K; Varini M
    Cancer Treat Rev; 1985 Mar; 12(1):1-47. PubMed ID: 3896483
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical pharmacology and toxicology of estramustine phosphate.
    Müntzing J; Gunnarsson K
    Urology; 1984 Jun; 23(6 Suppl):6-10. PubMed ID: 6375082
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of the preclinical antitumor activity and toxicology of L-asparaginase derived from E. coli.
    Charles LM; Bono VH
    Cancer Treat Rep; 1981; 65 Suppl 4():39-46. PubMed ID: 7049380
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects.
    Greco C; Corsi A; Caputo M; Cavallari A; Calabresi F
    Tumori; 1979 Apr; 65(2):169-80. PubMed ID: 462569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report on carcinogenesis bioassay of isophosphamide.
    Am Ind Hyg Assoc J; 1978 Jun; 39(6):A12, A14, A16. PubMed ID: 685821
    [No Abstract]   [Full Text] [Related]  

  • 10. Circadian variation in the susceptibility of male Balb/C mice to ifosfamide.
    Snyder NK; Smolensky MH; Hsi BP
    Chronobiologia; 1981; 8(1):33-44. PubMed ID: 7238180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of the DS-carcinosarcoma in the rat with ifosfamide/dimethylsulfoxide].
    von Ardenne M; Reitnauer PG
    Pharmazie; 1975 Sep; 30(9):602-5. PubMed ID: 1187742
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N; Stekar J
    Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical toxicology protocols of the Laboratory of Toxicology.
    Prieur DJ; Young DM; Davis RD; Cooney DA; Guarino AM
    Natl Cancer Inst Monogr; 1977 Mar; (45):159-77. PubMed ID: 412104
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.
    Brock N; Pohl J; Stekar J
    Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1155-63. PubMed ID: 7199463
    [No Abstract]   [Full Text] [Related]  

  • 15. Toxicological aspects of cyclamate and cyclohexylamine.
    Bopp BA; Sonders RC; Kesterson JW
    Crit Rev Toxicol; 1986; 16(3):213-306. PubMed ID: 2420530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities].
    Ardenne M; Reitnauer PG
    Arzneimittelforschung; 1975 Sep; 25(9):1369-79. PubMed ID: 22
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB x NZW) mice. II. Emergence of tumors in young animals treated with azathioprine and ifosfamide, including a histologic assessment of the neoplasms.
    Mitrou PS; Fischer M; Mitrou G; Röttger P
    Arzneimittelforschung; 1979; 29(4):662-7. PubMed ID: 582763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
    Paprocka M; Kuśnierczyk H; Budzyński W; Rak J; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):275-84. PubMed ID: 3592931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapeutic activity of ifosfamide in 6 different isologously transplanted experimental tumours of BD-rats (author's transl)].
    Stekar J
    Arzneimittelforschung; 1976; 26(10):1793-7. PubMed ID: 191035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicology of clobazam.
    Schütz E
    Br J Clin Pharmacol; 1979; 7 Suppl 1(Suppl 1):33S-35S. PubMed ID: 35202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.